Kornimate/medical-research-clean huggingface dataset:
extended follow up of the targit-a trial

Conditions: Breast Neoplasm Female

Summary: all uk patients who participated in the targit-a trial were initially treated for early breast cancer between 2000-2012. a total of 3451 patients from 33 hospitals in 11 countries participated in the trial and a comparison was made between traditional radiotherapy given over several weeks (external beam radiotherapy, ebrt) with targeted intraoperative radiotherapy (targit-iort) as a single dose given during the operation to remove the breast cancer. the trial was funded by the health technology assessment (hta) programme of the department of health, uk and sponsored by university college london. the results from this trial have been published in major medical journals and have already started changing the way breast cancer in treated around the world; please see www.targit.org.uk for more details. we would like to continue to collect data about the health status of all patients to enable us to learn about longer term differences in the effects of these treatments on health. an analysis of this information could improve treatment for patients with breast cancer. for this, hta have granted us further funding.


Eligibility criteria:
inclusion criteria: * all patients who participated in the targit-a trial (nct00983684). exclusion criteria: * any patient who has withdrawn consent for further follow-up, or died.

Keywords: intra-operative radiation therapy
prospective cohort observational study of placenta accreta spectrum disorders

Conditions: Placenta Accreta Spectrum Disorders,Previous Cesarean Section

Summary: the incidence of placenta accreta spectrum disorders has shown an increasing trend worldwide due to the increase of cesarean section rate. research on the outcomes of placenta accreta spectrum disorders primarily relies on retrospective analysis. the aim of this study was to establish a prospective, multicenter cohort in china in order to conduct further investigations on the clinical features, predictive capabilities, diagnostic methods, and pathogenesis of placenta accreta spectrum disorders.


Eligibility criteria:
inclusion criteria: 1. pregnant women aged 18-45; 2. at least one previous cesarean section ,regular antenatal examination and plan to give birth at research center 3. sign informed consent exclusion criteria: irregular antenatal examination; twins; autoimmune diseases; prepregnancy hypertension; prepregnancy diabetes mellitus; inheritance sexual diseases; tumor; abnormal liver and kidney function in early pregnancy

Keywords: placenta accreta spectrum disorders；previous cesarean section
use of mri and ctbs for catatonia in autism

Conditions: Autism Spectrum Disorder; Catatonia; Intellectual Disability

Summary: despite the significant morbidity and mortality associated with catatonia in autism, no diagnostic research has attempted to identify biomarkers for catatonia. this application will use a participant's own individual brain magnetic resonance image to target the primary motor strip with transcranial magnetic stimulation; to determine if hyper-excitability of the brain directly correlates with symptoms of catatonia and social-emotional impairment in autism. completion of this project would result in the first study to associate hyper-excitability of the brain with catatonia and core features of autism; findings which are likely to have a significant impact on the health and well-being of autistic individuals.


Eligibility criteria:
inclusion criteria: * individuals aged 15-40 years of age will be enrolled. this age range was selected given the high degree of social development occurring in this life stage, the developmental nature of asd, and ongoing ctbs-induced changes in mep amplitude observed in aic individuals as they age. * subjects and/or guardians must also be fluent in english, diagnosed with asd based on dsm-5 criteria1 and autism diagnostic observation schedule-ii (ados-ii) assessment,78 and competent to assent to the study based on investigator clinical evaluation. consenting guardians will be included if indicated. * subjects, or guardians if subjects cannot consent, must be competent to consent to the study. subjects must be able to assent to the study as determined by clinical evaluation from the primary investigator. exclusion criteria: * history of substance abuse/dependence, * history of concomitant major medical/neurologic illness * history of seizure within one calendar year * history of traumatic brain injury * pregnant or currently breastfeeding * are psychiatrically or medically unstable as determined by the investigator clinical evaluation * prescribed medication contraindicated in tms * have a history of tms treatment. * are diagnosed with a syndrome which results in asd symptoms as preliminary research suggests individuals with these diagnoses have differing biomarker responses to tms.26 * children below the age of fifteen will also be excluded because of decreased likelihood of remaining still in the mri scanner, as well as for scientific reasons surrounding unknown variability for key variables during pubertal onset. * mri scanning also introduces exclusionary criteria for conditions contraindicated to mri, thus individuals with any bodily metal, history of claustrophobia, or pacemakers will be excluded. * expresses dissenting behaviors as outlined below.
efficacy and safety of the flow diverter (tonbridge) for endovascular treatment of intracranial aneurysms

Conditions: Intracranial Aneurysm

Summary: the purpose of this study is to assess the efficacy and safety of the flow diverter (tonbridge) for endovascular treatment of intracranial aneurysms.

this is a prospective, multi-center, randomized, open, positive-controlled, non-inferiority trial. this clinical trial is conducted at more than 5 centers in china. eligible patients are randomized into experimental group using flow diverter (tonbridge) or control group using tubridge (microport) in a 1:1 ratio. the primary objective of this study is to verify the complete occlusion rate of aneurysms at 12 months of flow diverter (tonbridge) is non-inferior to tubridge, for treatment of intracranial aneurysms, and evaluate the effectiveness and safety of the flow diverter (tonbridge).

Eligibility criteria:
inclusion criteria: * age 18 to 80 years, any gender; * unruptured intracranial aneurysms locate in the internal carotid artery (ica) or vertebral artery (va) with a neck ≥ 4 mm and a maximal diameter ≥ 10 mm, which diagnosed by dsa; * the target aneurysm with a parent vessel diameter of 2.0-6.5 mm; * subject or guardian is able to understand the purpose of study, shows sufficient compliance with the study protocol and provides a signed informed consent form. exclusion criteria: * diagnosed as multiple aneurysms which cannot be covered by a single stent or with cerebrovascular malformations; * subarachnoid hemorrhage of the target aneurysm within 30 days pre-procedure; * modified rankin scale (mrs) score \> 2 in pre-procedure; * platelet (plt) \ 1.5; * heart, lung, liver and renal failure or other severe diseases (such as brain tumor, systemic infection, disseminated intravascular coagulation, myocardial infarction within 12 months before enrollment, history of severe psychosis); * the lesion which is not appropriate for flow diverter delivery and deployment judged by investigators (severe stenosis of parent artery, severe tortuosity of parent artery, stent failing to reach the lesion, etc.); * major surgery within 30 days before enrollment, or intending to receive surgery within 180 days after enrollment; * allergic history of anesthetics and contrast agents, or contraindication for dual antiplatelet or/and anticoagulant therapy; * allergic history of metals such as nickel-titanium alloy; * life expectancy \< 12 months; * pregnant or breastfeeding women; * subject has participated in other drug or medical device clinical trials within 1 month before signing informed consent; * other conditions judged by the investigators as unsuitable for enrollment.
transcendental meditation and reduced trauma symptoms in women inmates

Conditions: Stress Disorders, Post-Traumatic

Summary: the pilot study investigates the potential benefits of the transcendental meditation program in reducing trauma, including ptsd, in female prisoners. subjects will be randomly assigned to either the tm program or a wait list control group for a period of four months.

this randomized controlled pilot study will evaluate the effects of transcendental meditation ® (tm) on female offenders with trauma. twenty-two inmates at the coffee creek correctional facility in wilsonville, oregon, with at least four months left of incarceration, will be enrolled in the study. subjects will be randomly assigned to either a tm (n=11) or a wait-list control group (n=11). subjects will be measured at baseline and four-month posttest, using the posttraumatic stress disorder checklist-civilian version (pcl-c) twenty of the subjects (10 in each group) will take part in their treatment assignment and complete post-testing.

Eligibility criteria:
inclusion criteria: * female inmates, at least 4 months left of incarceration, signed written informed consent prior to baseline testing exclusion criteria: * none

Keywords: meditation tm ptsd trauma female prisoners
safety and efficacy of human mesenchymal stem cells for treatment of liver failure

Conditions: Liver Failure; Mesenchymal Stem Cells

Summary: liver failure (lf) is a dramatic clinical syndrome with massive necrosis of liver cells. and liver transplantation is the only available therapeutic option for patients suffering with this condition. however, lack of donors, surgical complications, rejection, and high cost are serious problems. previous study showed that bone marrow derived mesenchymal stem cells (bm-mscs) replace hepatocytes in injured liver, and effectively rescue experimental liver failure and contribute to liver regeneration. in this study, the patients with lf will undergo administration of human umbilical cord mesenchymal stem cells (uc-mscs) via peripheral vein transfusion to evaluate the safty and efficacy of uc-mscs treatment for these patients.

liver failure (lf) is a severe life-threatening condition, and is a dramatic clinical syndrome with massive necrosis of liver cells, and liver transplantation is the only available therapeutic option for patients suffering with this condition. however, lack of donors, surgical complications, rejection, and high cost are serious problems. since current therapeutic options for lf that is usually with extremely poor prognosis are still limited, recent studies indicate that mesenchymal stem cells (mscs), due to their function in immune modulation and liver-damage repair, are of great therapeutic potential for this disease. previous study showed that bone marrow derived mesenchymal stem cells (bm-mscs) replace hepatocytes in injured liver, and effectively rescue experimental liver failure and contribute to liver regeneration.the purpose of this study is to investigate the safety and initial efficacy of human umbilical cord msc (uc-mscs) treatment for patients with lf. in this study, mscs were isolated from umbilical cord and generated in appropriate growth medium. 50 lf patients with lf received i.v. transfusion of 0.5-1.0×106 cells/kg of mscs as the treated group and other 20 lf patients with lf were transfused with placebo without mscs as control group. all 70 of them received the routine management for liver failure. during the 2-year follow up, the evaluation of safty and efficacy will be undergone to help to establish innovative cell-based therapies for the treatment of diseases.

Eligibility criteria:
inclusion criteria: 1. aged 18-70 years 2. liver failure 3. negative pregnancy test (female patients in fertile age) 4. written consent exclusion criteria: 1. hepatocellular carcinoma or other malignancies 2. severe problems in other vital organs(e.g.the heart,renal or lungs) 3. pregnant or lactating women 4. severe bacteria infection 5. anticipated with difficulty of follow-up observation 6. other candidates who are judged to be not applicable to this study by doctors

Keywords: liver failure mesenchymal stem cells model for end-stage liver disease ascite serum albumin
pergolide treatment and valvular heart disease

Conditions: Heart Valve Diseases; Parkinson's Disease; Pergolide; Fibrosis

Summary: in a blinded echocardiographic study we investigate the frequency of valvular abnormalities in a group of parkinson patients treated with either ergot derived dopamine agonists (pergolide and cabergoline) or non-ergot derived dopamine agonists (pramipexole and ropinirole). the ability to detect patients with valvular abnormalities by clinical approach is examined.

some case reports and a single study, which included 78 parkinson patients, has found a correlation between treatment with the ergotamine derivative dopamine agonists (pergolide) and restrictive valvular heart disease. the mechanisms are thought to be the same as with the former used anorectikum, fenfluramine and other drugs stimulating the 5ht-2b receptor. in a blinded manner we make physiologic and echocardiographic examination on 160 parkinson patients treated with either ergotamine or non-ergotamine derivative dopamine agonists (80 patients in each group) to see whether parkinson patients treated with ergotamine derivatives have more heart valvular disease

Eligibility criteria:
inclusion criteria: * parkinson patients who in the last year has been treated minimum 6 months with either ergotamine derivative or non-ergotamine derivative dopamine agonists (the latter included as controls) * informed contests exclusion criteria: * control patients will be excluded if the have been treated with ergotamine derivates in the last 12 months or if the prior to that have had ergotamine derivates for more than 6 months * patients with known valvular heart disease prior to the diagnosis of parkinson

Keywords: pergolide ergotamine derivates valvular heart disease
investigating the effects of different soft tissue mobilizations on delayed onset muscle soreness

Conditions: Muscle Soreness

Summary: delayed onset muscle soreness (doms) is associated with the initiation of a new physical activity or a sudden increase in exercise volume and intensity. doms also occurs following eccentric exercises such as ballistic stretching, downhill running, weight training and plyometrics. doms might prevent performing sports and decreases the performance of professional or recreational athletes. recently, different soft tissue mobilization applications (massage, foam roller) have been preferred by many athletes to prevent doms. however, there is no study comparing the effects of these techniques on doms. therefore, the aim of the present study is to investigate the effects of different soft tissue mobilization practices on doms and sportive performance in recreational athletes. in order to achieve this goal, a total of 36 recreational athletes will be included and will be allocated to three groups as foam roller group (n=12), massage group (n=12) and control group (n=12). demographic data, thermal camera measurements, fatigue level assessments, and performance measurements will be performed. all measurements will be carried out four times as before the application, immediately after the application, after 24 hours and after 48 hours.

after being invited to the study, the demographic data of all participants who agreed to participate in the study will be recorded on a structured form. participants will be randomly divided into three groups: massage application group, foam roller application group and control group. afterwards, thermal imaging, perceived fatigue and pain level, blood lactate level measurements, and vertical jump assessments will be done for the quadriceps femoris muscle. then, the fatigue protocol will be applied for the quadriceps femoris muscle and five-minute applications will be made according to the groups in which they are randomly separated. evaluations made in the first applications will be made immediately after the applications, 24 hours and 48 hours later, as the 2nd, 3rd and 4th measurements. the assessor will not know which group the participants are from.

Eligibility criteria:
inclusion criteria: * performing recreational sports at least 1 and at most 3 times a week. exclusion criteria: * any musculoskeletal, neurological or other serious health problems experienced in the past six months * not willing to participate in the study

Keywords: recreational athlete soft tissue mobilization delayed onset muscle soreness
measurement properties of the turkish version of the low back pain knowledge questionnaire

Conditions: Low Back Pain; Knowledge, Attitudes, Practice

Summary: this study aims to assess the validity and reliability of the turkish version of the low back pain knowledge questionnaire (lkq). this questionnaire is a comprehensive, disease-specific tool that evaluates knowledge about low back pain. adapting it into turkish will provide healthcare professionals with a valuable resource for assessing patient awareness, guiding educational programs, and improving clinical practices for low back pain management.

this study aims to evaluate the validity and reliability of the turkish version of the low back pain knowledge questionnaire (lkq), a comprehensive tool that assesses individuals' knowledge about the characteristics, symptoms, causes, and management of low back pain. the study will follow a systematic process, including translation, cultural adaptation, and psychometric evaluation. after translating the questionnaire using the forward-backward method, a panel of experts will review it for clarity and cultural relevance. the adapted questionnaire will be tested on a diverse sample to assess internal consistency (cronbach's alpha) and test-retest reliability. the results will provide a validated turkish version of the lkq, enabling healthcare professionals to assess patient knowledge, guide educational programs, and improve low back pain management and prevention strategies.

Eligibility criteria:
inclusion criteria: * 18 years old or over * turkish as their mother tongue * presence of back pain of any duration * volunteered to participate in the study exclusion criteria: * failure to complete the questionnaire

Keywords: reliability validity
development of pneumonia due to alveolar glucose levels in systemic hyperglycemia

Conditions: Glucose Metabolism Disorders; Pneumonia, Bacterial

Summary: incidence of pneumonia in patients with high systemic glucose levels.

clinical and mechanistic studies have shown that a hyperglycaemic metabolic condition is associated with a higher incidence of infection and consecutive increased morbidity and mortality. the underlying mechanisms in detail are not completely understood. so far it is not clear whether systemic increased glucose levels are caused by a stress reaction of the body through a catabolic metabolism situation as well as a "stress-induced insulin resistance", or infections are promoted by hyperglycemia. from in vivo and in vitro studies, a glucose threshold for the lung is known (147 mg / dl), similar to that in the kidney. it can be hypothesized, that an intra-alveolar glucose in turn promotes bacterial growth as a nutrient substrate. the aim of the study is to determine the concentration of glucose in the alveolar space in connection with hyperglycemic conditions, and to demonstrate a higher incidence of pneumonia in this patient group. the study will enroll cardiac surgery patients receiving surgical treatment and expected postoperative ventilation. systemic blood glucose monitoring is recorded throughout hospitalization, as well as the removal of bronchial aspirates intraoperatively and during ventilation to measure glucose levels and bacterial levels. the incidence of pneumonia is recorded during the postoperative period by means of radiological examinations and / or microbiological examinations.

Eligibility criteria:
inclusion criteria: * women and men over the age of 18 years * voluntary consent to study participation of the patient * planned cardiac surgery with expected endotracheal ventilation of ≥ 1 day postoperatively exclusion criteria: * age \<18 years * pregnancy * non-able-bodied patients (disempowerment / loss of consciousness, limitation of the ability to express one's own will, for example through disability) * subsequently withdrawn consent * accommodation in an institution on the basis of official or court orders * lack of or insufficient knowledge of german language, whereby the understanding of the written patient education is not guaranteed. * immunosuppressed patients * patients with a malignant disease

Keywords: pneumonia glucose infections respiratory tract infection hyperglycemia critical care
pioglitazone incretin study

Conditions: Diabetes Mellitus, Type 2

Summary: incretin hormones are hormones produced by the gut in response to food intake. these hormones help the body to control the metabolism of glucose (sugar). in particular, two incretin hormones (glp-1 and gip) cause the pancreas to secrete more insulin in response to high blood glucose levels. this helps the body to metabolize the glucose more effectively, lowering blood sugar levels. glp-1 and gip do not work as well in patients with type 2 diabetes (t2dm) as in subjects who do not have diabetes. this study tests whether a medicine called pioglitazone (actos), which is commonly used to treat t2dm, improves the ability of gip to increase insulin secretion. to address this question the investigators will recruit patients with t2dm whose diabetes is controlled with either diet and exercise or with metformin (another medicine commonly used to treat t2dm). subjects will undergo measurement of body fat by dexa scanning and a series of studies to characterize their metabolism. these studies include an oral glucose tolerance test (a test sometimes used to diagnose diabetes), a mixed-meal challenge (to measure how much glp-1 and gip are produced in response to a meal) and measurement of insulin secretion in response to glucose and gip given through a vein. the investigators will also obtain small samples of fat (from just under the skin of the belly) using a needle to measure levels of the receptor for gip. subjects will then be randomly assigned to 12 weeks of treatment with either pioglitazone or matching placebo (an inactive tablet that does not contain medication). the dose of pioglitazone will be increased during the first 4 weeks to the maximum prescribed dose of 45 mg per day. subjects will be seen every 2-4 weeks during the treatment phase of the study. after 12 weeks of treatment all studies performed at the beginning of the study will be repeated. the pioglitazone treatment will continue until the end of testing, approximately 4 weeks. the results of this study may give us information about why glucose control deteriorates in t2dm. this information might also lead to new ways to prevent or treat t2dm.


Eligibility criteria:
inclusion criteria: * type 2 diabetes controlled with diet+exercise or metformin monotherapy * hba1c less than or equal to 7% * women will be non-fertile or practicing birth control exclusion criteria: * acute or chronic medical conditions that would contraindicate participation * class iii or iv heart failure * pregnant or nursing women * patients taking antidiabetic medications other than metformin, oral or chronic topical steroids, weight loss agents, antipsychotics, or other drugs that could affect insulin sensitivity or secretion. * ast or alt more than 2.5 times the upper limit of normal * active alcohol or drug abuse * weight greater than 300 pounds

Keywords: diabetes pioglitazone gip